Actions

GLP-1 weight loss shots NYC

From W8MD weight loss and sleep centers

Affordable physician-supervised GLP-1 weight loss shots, insurance visits, prior authorization support, and self-pay options in Brooklyn and New York City


GLP-1 Weight Loss Shots NYC
Affordable, physician-supervised Semaglutide, Tirzepatide, Wegovy, Zepbound, and other medical weight-loss options in Brooklyn and New York City

Semaglutide from $29.99/week and up* Tirzepatide from $45/week and up*

*Budget pricing when insurance is accepted for qualifying medical visits. Self-pay options are also available.

Call Brooklyn: (718) 946-5500 Request an appointment

Most insurances accepted
For qualifying medical visits
Prior authorization help
When coverage and eligibility criteria apply
Affordable alternatives
When insurance does not cover medication
Brooklyn office
Serving all five NYC boroughs
Affordable GLP-1 weight loss shots at W8MD in Brooklyn and New York City.

GLP-1 weight loss shots in NYC are available through W8MD Weight Loss, Sleep and MedSpa for eligible adults seeking physician-supervised treatment for obesity, overweight, increased appetite, food noise, insulin resistance, type 2 diabetes, and related weight-associated medical conditions.

W8MD offers comprehensive medical weight loss care from its Brooklyn office, serving patients from Brooklyn, Manhattan, Queens, Staten Island, the Bronx, Long Island, and nearby New York communities.

Depending on medical eligibility, insurance coverage, medication availability, and provider recommendation, treatment may include:

Affordable NYC GLP-1 pricing:

  • Semaglutide: from $29.99 per week and up when insurance is accepted for qualifying medical visits
  • Tirzepatide: from $45 per week and up when insurance is accepted for qualifying medical visits
  • Self-pay Semaglutide: from $59.99 per week and up
  • Self-pay Tirzepatide: from $69.99 per week and up

Starting prices generally apply to entry-level doses. Pricing may increase with dose and may vary according to medical eligibility, medication selection, pharmacy availability, required visits, and individualized treatment needs.

Quick navigation

W8MD GLP-1 pricing in NYC

W8MD offers several pathways for patients seeking affordable GLP-1 treatment in New York City.

Treatment pathway Starting price Important information
Semaglutide with insurance accepted for visits From $29.99/week and up For eligible patients using insurance for qualifying physician-supervised medical visits. Price may increase with dose.
Tirzepatide with insurance accepted for visits From $45/week and up For eligible patients using insurance for qualifying medical visits. Price may increase with dose.
Self-pay Semaglutide From $59.99/week and up Available for qualifying patients who do not have visit coverage or prefer a fully self-pay pathway.
Self-pay Tirzepatide From $69.99/week and up Available when medically appropriate and subject to medication and pharmacy availability.
Brand-name Wegovy Depends on insurance or pharmacy price Coverage, copay, deductible, formulary status, and prior authorization requirements vary.
Brand-name Zepbound Depends on insurance or pharmacy price Coverage may depend on BMI, comorbid conditions, employer benefits, and plan-specific criteria.
Oral GLP-1 medications Varies Options may include Wegovy tablets or Foundayo when medically appropriate and available.

Important pricing notice: These are starting prices, not guaranteed prices for every patient or dose. Medication costs, medical visits, program fees, laboratory testing, pharmacy fees, insurance copays, deductibles, and higher-dose costs may be separate.

Insurance coverage for GLP-1 shots

Template:Main

W8MD accepts most insurance plans for qualifying medical weight-loss visits. Coverage may include some or all of the following, depending on the patient's plan:

Coverage for the office visit does not automatically mean that the insurance plan covers Wegovy, Zepbound, or another weight-loss medication. Medical benefits and pharmacy benefits may have different coverage rules.

Patients may still be responsible for:

  • Copays
  • Coinsurance
  • Deductibles
  • Noncovered services
  • Medication costs
  • Program fees
  • Pharmacy charges

Patients should confirm participation, benefits, and out-of-pocket costs with their insurance carrier.

GLP-1 prior authorization assistance

Template:Main

When an insurance plan covers GLP-1 weight-loss medication and a patient qualifies based on the plan's BMI and comorbidity requirements, W8MD can help obtain a prior authorization by documenting medical necessity and submitting the required clinical information.

A prior authorization may require documentation of:

  • Current height and weight
  • Body mass index
  • Previous weight-loss attempts
  • Previous medications
  • Duration of obesity or overweight
  • Participation in a supervised weight-management program
  • Nutrition and physical-activity efforts
  • Weight-related comorbid conditions
  • Contraindications to alternative medications
  • Continued weight loss or maintenance for renewal requests

Common qualifying criteria may include:

  • BMI of 30 kg/m² or higher; or
  • BMI of 27 kg/m² or higher with at least one qualifying weight-related medical condition

Potential qualifying comorbid conditions may include:

Insurance criteria vary. Some plans use different BMI thresholds, require step therapy, require participation in a structured program, or exclude weight-loss medication altogether.

Prior authorization is not guaranteed. W8MD can document eligibility and submit the necessary medical information when coverage is available, but the final approval or denial is made by the insurance company.

What if insurance does not cover GLP-1 medication?

Insurance plans may deny medication coverage because:

  • Weight-loss medications are excluded from the employer's plan
  • The medication is not on the plan formulary
  • The patient does not meet the plan's BMI threshold
  • The patient does not have a qualifying comorbid condition
  • Step therapy has not been completed
  • Documentation requirements have not been met
  • The plan requires use of a different medication
  • The requested product is considered nonpreferred
  • Coverage is limited to treatment of type 2 diabetes

If insurance coverage is unavailable or the patient does not meet the insurance company's prior-authorization criteria, W8MD offers affordable semaglutide- and tirzepatide-based pathways when medically appropriate:

  • Semaglutide from $29.99 per week and up when insurance is accepted for the qualifying medical visits
  • Tirzepatide from $45 per week and up when insurance is accepted for the qualifying medical visits
  • Self-pay Semaglutide from $59.99 per week and up
  • Self-pay Tirzepatide from $69.99 per week and up

A note about the term “generic GLP-1”

Patients frequently search for “generic Semaglutide,” “generic Ozempic,” “generic Wegovy,” “generic Tirzepatide,” or “generic Zepbound.” However, an alternative or compounded product is not automatically an FDA-approved generic equivalent.

The FDA distinguishes FDA-approved generic medications from compounded drugs. Compounded medications are not reviewed and approved by the FDA for safety, effectiveness, or manufacturing quality in the same manner as FDA-approved products.<ref name="FDAGenericCompounded">FDA warns companies against illegal marketing of compounded GLP-1 medications(link). U.S. Food and Drug Administration.2026-03-03.Accessed 2026-07-22.</ref>

W8MD therefore uses terms such as affordable Semaglutide-based option, Tirzepatide-based option, or self-pay GLP-1 pathway unless a medication is an FDA-approved generic.

Patients should obtain prescription medications only through legitimate medical care and appropriately licensed pharmacies.

What are GLP-1 weight loss medications?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring incretin hormone that participates in:

GLP-1 receptor agonists and related incretin medications may support weight loss by:

  • Reducing hunger
  • Improving fullness after meals
  • Helping patients become satisfied with smaller portions
  • Reducing cravings and persistent food noise
  • Delaying stomach emptying
  • Supporting blood-glucose regulation
  • Making it easier to follow a reduced-calorie eating plan

Tirzepatide is commonly grouped with GLP-1 medications, but it is more precisely a dual GIP and GLP-1 receptor agonist.

Medication works best when combined with nutrition counseling, adequate protein, physical activity, resistance training, sleep optimization, behavioral support, and a long-term maintenance plan.

FDA-approved GLP-1 weight loss injections

Template:Main

Wegovy injection

Wegovy is an FDA-approved once-weekly semaglutide injection for chronic weight management in eligible patients. It is used with a reduced-calorie diet and increased physical activity.

Wegovy may reduce appetite, improve satiety, reduce food intake, and help selected patients achieve clinically meaningful weight loss. It also has a cardiovascular risk-reduction indication for certain adults with established cardiovascular disease and overweight or obesity.<ref name="WegovyLabel">Wegovy prescribing information(link). U.S. Food and Drug Administration.Accessed 2026-07-22.</ref>

Ozempic also contains semaglutide, but Ozempic is primarily approved for type 2 diabetes and selected risk-reduction indications. Wegovy is the semaglutide brand approved specifically for chronic weight management.

Related pages:

Wegovy HD

Wegovy HD is a higher-dose 7.2 mg semaglutide injection approved for weight loss and long-term weight maintenance in certain adults. It is not a starting dose and is not appropriate for every patient.<ref name="WegovyHDFDA">FDA approves higher-dose Wegovy HD(link). U.S. Food and Drug Administration.2026-03-19.Accessed 2026-07-22.</ref>

Patients should not increase their Semaglutide dose without medical direction. Dose selection depends on response, side effects, previous treatment, medical conditions, and provider judgment.

Zepbound

Zepbound is an FDA-approved once-weekly tirzepatide injection for chronic weight management in eligible adults with obesity or overweight and at least one weight-related medical condition.<ref name="ZepboundFDA">FDA approves Zepbound for chronic weight management(link). U.S. Food and Drug Administration.2023-11-08.Accessed 2026-07-22.</ref>

Tirzepatide activates both GIP and GLP-1 receptors. It may reduce appetite, improve satiety, decrease calorie intake, improve blood-glucose regulation, and produce substantial weight reduction in selected patients.

Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Mounjaro contains the same active ingredient, tirzepatide, but is approved for type 2 diabetes. Zepbound is the tirzepatide brand approved for chronic weight management and qualifying obstructive sleep apnea.

Related pages:

Saxenda

Saxenda is an FDA-approved daily liraglutide injection used for chronic weight management in eligible patients. Unlike once-weekly Wegovy and Zepbound, Saxenda is administered daily.

Medication selection may depend on effectiveness, side effects, insurance coverage, availability, injection preference, and medical history.

FDA-approved GLP-1 weight loss pills

Not all current GLP-1 weight-loss medications require an injection.

Wegovy pill

The Wegovy pill is an oral Semaglutide formulation approved for chronic weight management in eligible adults. It provides a non-injection alternative for appropriate patients.

Wegovy tablets and Wegovy injections contain Semaglutide, but they have different formulations, doses, administration requirements, and absorption characteristics. Patients should not substitute one formulation for another without medical guidance.

Foundayo

Foundayo is the brand name for orforglipron, an FDA-approved oral GLP-1 receptor agonist for chronic weight management in eligible adults with obesity or overweight and at least one weight-related comorbidity.<ref name="FoundayoFDA">FDA approves Foundayo for chronic weight management(link). U.S. Food and Drug Administration.2026-04-01.Accessed 2026-07-22.</ref>

Foundayo is a tablet used with reduced-calorie nutrition and increased physical activity. Eligibility, availability, insurance coverage, and individual appropriateness vary.

Rybelsus

Rybelsus is an oral Semaglutide medication approved for type 2 diabetes and selected risk-reduction indications. It should not be confused with Wegovy tablets, which have a weight-management indication.

Emerging GLP-1 medications

Retatrutide

Retatrutide is an investigational once-weekly injection that activates three metabolic receptors:

  1. GLP-1 receptor
  2. GIP receptor
  3. Glucagon receptor

Retatrutide is being studied for obesity and several related conditions. It remains investigational and is not FDA-approved for routine prescribing or public use.<ref name="RetatrutideLilly">What to know about retatrutide(link). Eli Lilly and Company.2026-06.Accessed 2026-07-22.</ref>

Retatrutide warning: Do not purchase or inject products advertised online as “retatrutide,” “research retatrutide,” “triple-G,” or research peptides. Retatrutide is not approved for routine patient treatment and should be used only in a legitimate authorized clinical trial.

W8MD does not advertise retatrutide as an available treatment. Patients interested in emerging medications can discuss currently approved alternatives.

CagriSema

CagriSema is an investigational combination of Semaglutide and cagrilintide, an amylin analogue. Its final safety, effectiveness, dosing, availability, and regulatory status must be established through clinical trials and regulatory review.

Who may qualify?

Potential candidates for chronic weight-management medication commonly include adults with:

  • A BMI of 30 kg/m² or higher; or
  • A BMI of 27 kg/m² or higher with at least one weight-related medical condition

However, insurance companies may use different or more restrictive criteria.

W8MD evaluates more than BMI alone. An assessment may include:

  • Weight history
  • Waist measurement
  • Body composition
  • Previous diet and exercise efforts
  • Previous medications
  • Appetite, cravings, and food noise
  • Current prescriptions
  • Medical conditions
  • Family history
  • Sleep duration and sleep quality
  • Symptoms of sleep apnea
  • Emotional or binge eating
  • Laboratory results
  • Personal treatment goals

Who should not use GLP-1 medication?

GLP-1 and related medications are not appropriate for every patient. Depending on the product, important considerations may include:

Eligibility must be determined through an individualized medical evaluation.

Common side effects

Common side effects may include:

Gradual dose escalation, smaller meals, hydration, adequate fiber when appropriate, and avoiding heavy or high-fat meals may improve tolerability for some patients.

Patients should seek prompt medical care for persistent vomiting, dehydration, severe abdominal pain, yellowing of the skin or eyes, severe allergic symptoms, fainting, or another concerning reaction.

More than medication

Successful medical weight management combines medication with nutrition, activity, sleep, and long-term follow-up.

W8MD is not limited to prescribing an injection. Treatment may include:

Patients taking appetite-reducing medication still need adequate protein, fluid, vitamins, minerals, and nutrient-dense foods. Excessively low food intake may contribute to fatigue, constipation, nutritional deficiencies, or loss of muscle.

W8MD results and testimonials

Before-and-after weight-loss results from a W8MD patient. Individual results vary.

W8MD has provided physician-supervised weight-management care since 2011 and has helped thousands of patients work toward weight loss and long-term maintenance.

“Fantastic Program. Truly A Life Changer!”
— D.M., who lost 100 pounds with W8MD and maintained the weight loss for more than 10 years

Patients commonly value:

  • Physician-supervised treatment
  • Individualized medication choices
  • Improved appetite control
  • Reduced cravings and food noise
  • Accountability and follow-up
  • Nutrition support
  • Help managing side effects
  • Assistance with weight-loss plateaus
  • Long-term maintenance planning

See weight loss success stories, GLP-1 success stories, weight loss reviews, and before and after weight loss pictures.

Results disclaimer: Testimonials describe individual experiences. Results are not guaranteed and vary according to medication, dose, adherence, medical conditions, nutrition, activity, treatment duration, and individual response.

Why choose W8MD in New York City?

The W8MD medical team provides physician-supervised weight-loss, sleep-medicine, and MedSpa care.

Most insurances accepted for visits

W8MD accepts most insurance plans for qualifying medical weight-loss visits. Copays, deductibles, participation, referrals, and covered services vary.

Prior authorization support

When medication coverage is available and the patient satisfies the insurer's BMI and comorbidity criteria, W8MD can submit the medical documentation needed to help obtain prior authorization.

Affordable alternatives

Patients without medication coverage or who do not meet prior-authorization criteria may be evaluated for affordable Semaglutide- or Tirzepatide-based pathways.

More than 20 years of clinical experience

W8MD physicians have more than 20 years of experience helping patients with medical weight management, metabolic health, and related medical conditions.

Multiple prescription options

Patients who do not qualify for or tolerate GLP-1 medication may be evaluated for:

Weight loss and sleep care together

Insufficient sleep and untreated sleep apnea can contribute to fatigue, appetite dysregulation, difficulty exercising, high blood pressure, insulin resistance, and difficulty maintaining weight loss.

W8MD can evaluate eligible patients for:

Brooklyn and New York City location

W8MD Weight Loss, Sleep and MedSpa — Brooklyn / New York City

Address:
2632 East 21st Street
Suite L3
Brooklyn, New York 11235

Phone: (718) 946-5500

Services may include:

  • Physician-supervised medical weight loss
  • Semaglutide and Tirzepatide treatment
  • Wegovy and Zepbound evaluation
  • GLP-1 insurance prior authorization
  • Traditional prescription weight-loss medications
  • Nutrition and meal-replacement programs
  • Weight-loss maintenance
  • Sleep-apnea screening and testing
  • Medical-aesthetics and MedSpa services

W8MD's Brooklyn office serves patients searching for:

  • GLP-1 shots Brooklyn
  • GLP-1 weight loss shots NYC
  • Semaglutide NYC
  • Semaglutide Brooklyn
  • Tirzepatide NYC
  • Tirzepatide Brooklyn
  • Wegovy doctor NYC
  • Wegovy doctor Brooklyn
  • Zepbound NYC
  • Zepbound Brooklyn
  • Ozempic weight-loss education NYC
  • Mounjaro weight-loss education NYC
  • Affordable weight-loss injections NYC
  • Medical weight-loss doctor NYC

Patients may travel from:

Frequently asked questions

How much does Semaglutide cost at W8MD NYC?

Semaglutide-based options start from $29.99 per week and up when insurance is accepted for qualifying medical visits. The fully self-pay Semaglutide pathway starts from $59.99 per week and up.

How much does Tirzepatide cost at W8MD NYC?

Tirzepatide-based options start from $45 per week and up when insurance is accepted for qualifying medical visits. The fully self-pay Tirzepatide pathway starts from $69.99 per week and up.

Does W8MD accept insurance for weight-loss visits?

Yes. W8MD accepts most insurance plans for qualifying medical weight-loss visits. Participation, copays, deductibles, referrals, and covered services vary by plan.

Can W8MD obtain prior authorization for Wegovy or Zepbound?

When the insurance plan covers the requested medication and the patient meets the plan's BMI, comorbidity, and other medical criteria, W8MD can document medical necessity and submit a prior authorization. Final approval is controlled by the insurance company.

What happens if I do not meet my insurance company's BMI criteria?

W8MD can evaluate you for self-pay Semaglutide or Tirzepatide pathways, other FDA-approved medications, traditional prescription weight-loss medications, nutrition programs, and additional evidence-based options.

Does insurance coverage for my visit mean it will cover the medication?

No. Office visits and prescription medications may be governed by different insurance benefits. A plan may cover the medical visit while excluding weight-loss medication.

Does W8MD offer generic Ozempic or generic Zepbound?

Patients often use the word “generic” when referring to lower-cost Semaglutide- or Tirzepatide-based options. However, compounded or alternative products are not necessarily FDA-approved generic versions of Ozempic, Wegovy, Mounjaro, or Zepbound. W8MD discusses the exact medication pathway, source, risks, costs, and regulatory status during the evaluation.

Can W8MD prescribe Wegovy or Zepbound?

W8MD providers may evaluate eligible patients for Wegovy, Zepbound, and other weight-management medications. Prescribing depends on medical history, contraindications, diagnosis, availability, and provider judgment.

Is Ozempic approved specifically for weight loss?

Ozempic contains Semaglutide but is primarily approved for type 2 diabetes and selected risk-reduction indications. Wegovy is the Semaglutide brand specifically approved for chronic weight management.

Is Mounjaro approved specifically for weight loss?

Mounjaro contains Tirzepatide and is approved for type 2 diabetes. Zepbound contains Tirzepatide and is approved for chronic weight management and qualifying obstructive sleep apnea.

Does W8MD offer GLP-1 weight-loss pills?

W8MD can evaluate eligible patients for oral weight-loss medications, including Wegovy tablets, Foundayo, and other prescription options when appropriate and available.

Can I obtain Retatrutide from W8MD?

No. Retatrutide is investigational and not FDA-approved for routine prescribing. W8MD can discuss currently approved alternatives.

Will I regain weight if I stop treatment?

Weight regain can occur after medication is stopped. W8MD emphasizes nutrition, physical activity, muscle preservation, sleep optimization, appetite monitoring, behavioral support, and individualized GLP-1 maintenance therapy.

Request a Brooklyn or NYC appointment

Start Your NYC Medical Weight-Loss Journey

Ask about insurance-supported visits, GLP-1 prior authorization, Semaglutide from $29.99 per week and up, Tirzepatide from $45 per week and up, and fully self-pay options.

Call W8MD Brooklyn: (718) 946-5500

Related W8MD pages

GLP-1 treatment and insurance

New York medical weight loss

Nutrition, sleep, and maintenance

External links


```

Retrieved from "https://w8md.com/w/index.php?title=GLP-1_weight_loss_shots_NYC&oldid=6571"